Artificial Intelligence | News | Insights | AiThority
[bsfp-cryptocurrency style=”widget-18″ align=”marquee” columns=”6″ coins=”selected” coins-count=”6″ coins-selected=”BTC,ETH,XRP,LTC,EOS,ADA,XLM,NEO,LTC,EOS,XEM,DASH,USDT,BNB,QTUM,XVG,ONT,ZEC,STEEM” currency=”USD” title=”Cryptocurrency Widget” show_title=”0″ icon=”” scheme=”light” bs-show-desktop=”1″ bs-show-tablet=”1″ bs-show-phone=”1″ custom-css-class=”” custom-id=”” css=”.vc_custom_1523079266073{margin-bottom: 0px !important;padding-top: 0px !important;padding-bottom: 0px !important;}”]

GEN inCode Appoints Chief Financial Officer

GEN inCode UK Limited the privately-owned artificial intelligence cardiovascular disease company focused on the prevention of cardiovascular disease announces the appointment of Paul Foulger as Chief Financial Officer to the Company.

Recommended AI News: Schneider Electric’s NEO Network Announces Collaboration With Station A For New AI-Based DER Calculator To Drive Decarbonization In Member Facilities

Paul Foulger is an experienced CFO with a proven, demonstrable track record in the Biotech industry for both AIM listed and private companies. He is a strategic and commercially focussed leader with entrepreneurial experience at Board level across large and small companies with specific focus in recent years of pharmaceutical and diagnostic companies in the small to mid-cap space. Paul is a qualified certified accountant, having been Finance Director at NovaBiotics Ltd, Elsevier Science, Venn Life Sciences plc, and PredictImmune Ltd, amongst others; he has substantial lead transactional experience including IPO’s, reverse takeovers, divestments, over £100m of fundraising, and acquisitions in the UK, Europe and the US.

Related Posts
1 of 33,630

Recommended AI News: Liquidity Capital Has Announced Today The Closing Of A $10 Million Financing Agreement With HackerU

More recently, until December 2015, Paul was Group Finance Director at EKF Diagnostics Holdings plc, the global medical manufacturer of point-of-care and central lab devices and chemistry reagents; he is currently a non-exec director of Arcis Biotechnology Holdings Ltd and Autoclenz Ltd.

Matthew Walls, Executive Chairman and CEO, said: “We are delighted to welcome Paul to the Company and Executive team. Paul joins us at an exciting time in our development and will be instrumental to executing the delivery of the Company’s global growth strategy.”

Recommended AI News: Minute Media And Protected Media Collaborate To Empower Publishers By Solving Ad Fraud At The Source  

Leave A Reply

Your email address will not be published.